CMC is considered to be one of the world's advanced biomedical R&D center. In his exclusive interview with BioSpectrum's Raj Gunashekar, he shares some of the detailed information on companies and the research facilities offered at CMC, along with conducting clinical trials, and also about the future outlook of the biomedical R&D center.

Q: Can you comment on the companies at CMC and its facilities?
Mr Jiang Peng: As the only national level medical and hi-tech zone with the largest scale and the most complete industrial chain in China.

CMC is dedicated to pharmaceutical and biomedical field, which includes R&D, manufacturing, distribution, and healthcare treatment.

The major well-known multinational firms in our park are AstraZeneca, Takeda, Boehringer Ingelheim, Chugai Pharmaceutical, Sanofi Pasteur, and Nestle Health Science.

Besides, we've had business negotiations with other MNCs as well.

Q: What do you have in store for companies who want to conduct clinical trials in China?
Clinical trials should be conducted in a qualified three-level hospitals. CMC can help find the relevant hospitals in Jiangsu Province, and even all over China.

Besides, there are two three-level hospitals in Taizhou, which are now seeking approval. Once certificated, clinical trials could be held in these two hospitals.

Q: Can you discuss on the future outlook at CMC? What can we expect from CMC in the five years?
CMC is trying to attract 1000 companies with leading talents gathered in one place working on world-class and national level medical innovation.

In the next 5 years, CMC will greatly develop the diagnostic healthcare area, reagent base and medical devices base. The 5th phase pilot plant will see its construction phase complete and put into use for new companies.